基于托西利祖马布治疗移植患者的微血管炎症:一项回顾性研究
Johan Noble1,2,3, Giorgia Comai4,5, Valeria Corredetti4
1Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, University hospital Grenoble, Grenoble, France.
概括
托西利祖马布 (TCZ) 通过稳定估计的膜过率 (eGFR) 和减少慢性活性抗体中介排斥 (caAMR) 或微血管炎症 (MVI) 患者的捐赠者特异性抗体 (DSA) 来改善移植结果.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 移植免疫学 移植免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性活性抗体中介排斥 (caAMR) 是长期移植衰竭的主要原因.
- 现有的关于托西利祖马布 (TCZ) 的数据,一种抗IL-6受体抗体,用于caAMR治疗是相互矛盾的.
- 微血管炎症 (MVI) 没有捐赠者特异性抗体 (DSA) 和C4d沉积 (MVI + DSA-C4d-) 是另一种具有挑战性的情况.
研究的目的:
- 评估托西利祖马布 (TCZ) 作为移植患者的第一线治疗方法的疗效,患者患有caAMR或MVI + DSA-C4d-.
- 评估TCZ对估计的淋巴细胞过率 (eGFR) 轨迹和捐赠者特异性抗体 (DSA) 水平的影响.
主要方法:
- 在2018年7月至2023年9月期间接受TCZ治疗的64名成年移植患者的回顾性研究.
- 患者有caAMR或MVI + DSA-C4d-并接受TCZ作为第一线治疗.
- eGFR和DSA在TCZ启动前和之后被监测了一年;分析了组织学数据.
主要成果:
- TCZ治疗稳定了eGFR轨迹 (0.03 ± 0.2毫升/分钟/1.73毫升/月后TCZ与 -1.2 ± 0.2毫升/分钟/1.73毫升/月前TCZ; p = 0.001).
- 患有DSA的患者的百分比显著下降 (63.9%至38.9%;p < 0.001),也意味着MFI (9,537至7,250;p = 0.001).
- 年轻的年龄,MVI + DSA-C4d-表型,和较低的慢性结核病得分预测了TCZ反应.
结论:
- 对caAMR或MVI+DSA-C4d-脏移植接受者的一线TCZ治疗与改善的eGFR轨迹有关.
- TCZ治疗导致DSA和MFI的减少,以及组织学炎症的改善.
- 这些发现表明TCZ在管理这些特定的脏移植排斥情景方面具有潜在的治疗益处.
相关概念视频
01:28Kidney Transplant I: Introduction
65
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
65
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
64
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
64
01:26Kidney Transplant II: Surgical Procedure
78
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
78
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
01:16Kidney Transplant III: Nursing Management
88
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
88
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240